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Abstract: Breastfeeding is natural and the optimal basis of infant nutrition and development, with 
many benefits for maternal health. Human milk is a dynamic fluid fulfilling an infant’s specific 
nutritional requirements and guiding the growth, developmental, and physiological processes of 
the infant. Human milk is considered unique in composition, and it is influenced by several factors, 
such as maternal diet and health, body composition, and geographic region. Human milk stands as 
a model for infant formula providing nutritional solutions for infants not able to receive enough 
mother’s milk. Infant formulas aim to mimic the composition and functionality of human milk by 
providing ingredients reflecting those of the latest human milk insights, such as oligosaccharides, 
bacteria, and bacterial metabolites. The objective of this narrative review is to discuss the most recent 
developments in infant formula with a special focus on human milk oligosaccharides and 
postbiotics. 
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Nutrition in early infancy and childhood can significantly impact growth and development as 
well as immediate and later health [1]. The World Health Organization recommends exclusive 
breastfeeding for the first six months of life, followed by continued breastfeeding with appropriate 
complementary foods for up to two years or beyond [2]. Breastfeeding and/or nutritional intervention 
during early life can help prevent both infectious and non-communicable disease risk during 
childhood and into adulthood [1].  
A healthy gut development is of major importance during infancy. It contributes to growth and 
development by ensuring digestion and absorption of nutrients and fluids. The gut is also key in the 
development of immunity insofar as it maintains a barrier against infectious agents and interacts 
directly with the immune system to induce mucosal and systemic tolerance, which prevents of 
allergy. Furthermore, the gut provides signals to the brain to maintain a healthy state [3]. 
One of the major factors enabling proper gut function and development is a balanced gut 
microbiota [4]. Several prenatal and perinatal factors including mode of delivery, use of antibiotics, 
diet, and other environmental factors, including geographic region, may influence the microbial 
colonisation of the infant and in turn the maturation of the immune system, as reviewed elsewhere 
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[5]. Hence, it is generally agreed that the gut microbiota of the healthy, full-term, vaginally delivered 
and breastfed infant constitutes the gold standard for a favourable microbial composition in early life 
[6]. Since human milk contributes remarkably to the development of a balanced gut microbiota—
amongst many other health benefits—it is essential for infant formula to be as close to human milk 
as possible, providing bioactives targeting gut and immune health [7]. 
Two human milk oligosaccharides (HMOs), 2’-fucosyllactose (2’FL) and lacto-N-neotetraose 
(LNnT), are recent examples of optional ingredients being added to infant formula [8–11]. However, 
little attention has yet been given to 3'-galactosyllactose (3'-GL), which is an HMO present in human 
milk that may also naturally occur in fermented infant formula derived by milk fermentation [12,13]. 
This narrative review will focus on these most recent developments in infant formula as examples of 
‘biotics’ aiming to resemble human milk functions in infant formula. 
2. Oligosaccharides, Bacteria, and Microbial Metabolites in Human Milk 
Human milk contains many bioactive compounds such as oligosaccharides, immune cells, and 
varying levels of bacteria and their metabolites. They play an important role in the development of a 
healthy gut by supporting a favourable intestinal microbiota and in the development of the infant’s 
immune system [14–18]. 
2.1. Human Milk Oligosaccharides (HMOs) 
HMOs are pools of complex carbohydrates, the third most abundant component of human milk, 
and one example of naturally occurring ‘prebiotics’ [19]. Although originally characterised as HMOs, 
they are also present in the amniotic fluid, and thus the foetus is already exposed to HMOs prior to 
birth when ingesting the amniotic fluid [20–23].  
The quantity of HMOs in mature human milk is approximately 12–15 g/L as reported elsewhere 
[24,25]. There are more than 200 structurally different HMOs working together to deliver a combined 
beneficial effect, of which today more than 160 (neutral and acidic) types have been characterized in 
detail [26].  
Most HMOs escape digestion in the small intestine [16] and progress to the colon acting as decoy 
molecules binding pathogens and getting metabolised as ‘food’ for the commensal gut bacteria [27], 
such as bifidobacteria and lactic acid bacteria, allowing such bacterial populations to become more 
abundant [28]. Besides their prebiotic effect, HMOs also have direct effects on immune cells [29–32], 
block the routes of infections [30,33], provide building blocks for the brain [34], and stimulate 
intestine barrier functions, as published elsewhere [35]. 
HMOs are synthesised in the mammary gland by the prolongation of lactose with 
monosaccharides forming non-digestible trisaccharides (DP3) (degree of polymerisation, which is the 
amount of monosaccharide building blocks) or tetrasaccharides (DP4). The addition of sialic acids 
leads to two different sialyllactoses (SL), 3’-SL and 6’-SL (DP3), and the addition of fucose leads to 
two different fucosyllactoses (FL), 2’-FL and 3-FL (DP3), as well as difucosyllactose (DP4) [25,36,37] 
(Figure 1).  
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Figure 1. Chemical structure of neutral and acidic human milk oligosaccharides (HMOs) (adapted 
from Thurl et al. [25], Newburg et al. [38], and Urashima et al. [26]). 
HMOs also include galactosyllactoses (GLs), which appear in the form of several structurally 
distinct isomers and only differing in the glycosidic linkage of the terminal galactose added to lactose, 
leading to 3’-GL, 4’-GL, and 6‘-GL (DP3) [38,39] (Figure 2). Those HMOs can also be derived from 
lactose by the enzymatic activity of bacterial β-galactosidases, which splits lactose to glucose and 
galactose and catalyses the transgalactosylation of lactose to produce GLs [40–43]. Using an adapted 
approach of a recently published targeted liquid chromatography-tandem mass spectrometry 
method for HMOs, native GL-isomers like 3'-GL could be directly detected in human milk samples 
from various stages of lactation. The abundance of 3'-GL appeared to be relatively stable between 
colostrum and mature milks, whereas 6'-GL declined over time [44]. In general, HMO concentrations 
decline over time from colostrum to mature milk [45], including GLs [39,46]. Thurl et al. also found 
a slight decrease in HMOs within the first 90 days of lactation [47]; however, this might be partly 
compensated for by more volume of human milk being consumed by infants in the respective 
longitudinal setting. 
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Figure 2. Chemical structures of galactosyllactoses, 2’-FL, 3-FL, 3’-SL, 6’-SL, Lacto-N-tetraose (LNT), 
and lacto-N-neotetraose (LNnT) (adapted from Urashima et al. [48]). 
Larger HMO structures are derived by adding galactose and N-actetylglucosamine as 
disaccharide building blocks, which leads to tetrasaccharides (DP4), Lacto-N-tetraose (LNT), and 
Lacto-N-neotetraose (LNnT). Those tetrasaccharides can be further extended by those disaccharide 
units (DP6, DP8, etc.) and in addition decorated with further single or multiple fucose residues, 
leading to large neutral HMOs with a molecular size up to 8 kDa [49] and/or single or multiple sialic 
acid residues, leading to large acidic HMOs with a molecular size up to 3.6 kDa [50].  
Size exclusion chromatography, which was further used to describe the complexity of short- and 
long-chain HMOs, demonstrated a molecular size distribution of short-chain and long-chain HMOs 
in a ratio of 9:1 [49]. Long-chain HMOs are less easily fermented by the gut microbiota, whereas short-
chain HMOs are more active in the proximal parts of the gut [26], ensuring that potential substrates 
are available for the gut microbiota through the gastrointestinal tract, as shown for homo-polymeric 
fructans [51]. Although the long-chain HMOs are less abundant, they may exert a relevant bioactivity, 
which leads to the conclusion that abundance cannot automatically explain the biological importance 
of a molecule. 
2.2. Bacteria in Human Milk 
Human milk is also an important source of beneficial bacteria (naturally occurring ‘probiotics’) 
that help colonise the infant gut and contribute to the composition of a favourable gut microbiota, 
including Bifidobacterium spp. and Lactobacillus spp. [52,53], with genus Bifidobacterium dominating 
the gut microbiota of a vaginally delivered infant [54,55]. Bacteria in human milk are anticipated to 
be bioactive components regulating the development of an infant’s immune system and attenuating 
inflammation processes [56]. In general, the microbiome of human milk is a recent field of research, 
as explored elsewhere [53,56–59]. 
The total number of bacteria in human milk significantly differs according to detection methods. 
It has been estimated that human milk contains median values between 103 and 106 bacteria per 
millilitre [60–62]. The difference in number caused by different detection methods could be due to 
the fact that in molecular-based methods, DNA from non-viable bacteria and extracellular DNA can 
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also be amplified, suggesting that not only live bacteria but significant amounts of non-viable bacteria 
coexist in human milk [60]. 
2.3. Microbial Metabolites in Human Milk 
Besides bacteria, their metabolites (e.g., butyrate and other short-chain fatty acids (SCFAs), 
peptides, oligosaccharides) may also naturally pass into human milk, and this can be detected 
through metabolomics research using nuclear magnetic resonance spectroscopy [63,64]. Most 
recently these metabolites have gained more research attention that is focused on their possible role 
in shaping the growth and development of the infant. A widely accepted definition still needs to be 
agreed on, but in general, they may also be referred to as ‘natural postbiotics’ (comprising both 
inactivated bacterial cells and metabolites) and are anticipated to stimulate both healthy gut 
microbiota composition and function as well as immune functioning and development [60,64,65].  
3. The ‘Biotic’ Family: Resembling Human Milk Benefits in Infant Formula 
There is increasing research on nutritional postnatal interventions using probiotics, prebiotics, 
synbiotics, and the so-called postbiotics to promote the establishment of a beneficial microbiota and 
to have a positive impact on neonatal health (Figure 3). Whereas infant formulas can only provide 
static selections of these substances, the amount and composition are highly dynamic and individual 
in human milk [47,66,67]. This may be illustrated by the diversity of oligosaccharide structures in 
human milk, which has been shown to vary among women according to genetic factors, geographical 
regions, stages of lactation, and, potentially, maternal probiotic supplementation during the late 
stages of pregnancy [45,47,68]. For example, in women with the active gene for fucosyltransferase 2 
(FUT2, secretors), 2′-FL is by far the most abundant HMO, with a mean concentration of 2.7 g/L, and 
constitutes nearly 24% of all HMOs [25]. However, in the milk of women without the active gene for 
FUT2 (non-secretors), who make up 21% of all women in larger parts of the world, 2’-FL was not 
found [24,25,67].  
 
Figure 3. Definition of probiotics [69], prebiotics [70], synbiotics [71], and postbiotics [65] (adapted 
from Salminen et al. [72]). 
According to a recent consensus definition, probiotics are live microorganisms that confer a 
health benefit on the host when administered in adequate amounts [69], whereas prebiotics are 
defined as substrates that are selectively utilised by host microorganisms conferring a health benefit 
[70]. An official definition of synbiotics, which are a combination of both pro- and prebiotics [71], will 
soon be published by the International Scientific Association for Probiotics and Prebiotics (ISAPP). In 
contrast to pre- and probiotics, an official aligned global definition of postbiotics is still pending and 
will be discussed later in this paper. 
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3.1. Probiotics 
Most probiotic-containing infant formula comprise Bifidobacterium spp. and/or lactic acid 
bacteria such as Lactobacillus spp., which are generally regarded as safe for food use in the European 
Union based on the QPS-list (Qualitative Presumption of Safety) of bacteria. In the United States, a 
non-mandatory system of safety evaluation is in place, provided by the U.S. Food & Drug 
Administration (FDA). On request, it evaluates safety assessment filings of specific probiotic strains 
to be included in the so-called GRAS (Generally Recognized as Safe) Notice Inventory, which is 
continuously updated [73].  
There are data on specific probiotics in infant formula accompanied by a large diversity in study 
outcomes [74]. However, these health benefits are very strain and disease specific. For example, for 
preterm infants, the Committee on Nutrition of the European Society for Paediatric Gastroenterology 
and Nutrition (ESPGHAN) and the ESPGHAN Working Group for Probiotics and Prebiotics 
conditionally recommended the use of L. rhamnosus GG (LGG) ATCC 53103 (at a daily dose ranging 
from 1 x 109 CFU to 6 x 109 CFU) and the combination of B. infantis Bb-02, B. lactis Bb-12, and Str. 
thermophilus TH-4 (at a daily dose of 3.0 to 3.5×108 CFU of each strain) as it might reduce necrotizing 
enterocolitis (NEC) stage 2 or 3 in preterm infants (low certainty of evidence), but mortality and sepsis 
did not show any clear direction in effect size. However, no recommendation could be made in either 
direction regarding the use of L. reuteri DSM 17938 and the combination of B. bifidum NCDO 1453 
(currently reclassified as B. longum) with L. acidophilus NCDO 1748 (ATCC 4356, LA37, or NCIMB 
30316) in preterm infants to reduce the risk of mortality, NEC stage 2 or 3, or sepsis (very low certainty 
of evidence) [75]. For term born infants, in a review from 2011, the ESPGHAN Committee on 
Nutrition did not recommend the routine use of probiotic- and/or prebiotic-supplemented infant 
formulas, identifying further need for well-designed and carefully conducted randomised controlled 
trials [74]. 
3.2. Prebiotics 
Because of their stability, low risk of adverse effects, ease of administration, and potential for 
influencing the composition and function of the microbiota in the gut and beyond, the clinical 
applications of prebiotics are expanding [76].  
In last decades, different prebiotic mixtures of galacto-oligosaccharides (GOS) and fructo-
oligosaccharides (FOS) have been studied. Globally the most studied prebiotic mixture of 
oligosaccharides in infant formula consists of short-chain (sc) GOS and long-chain (lc) FOS, 
scGOS/lcFOS (9:1). The mix is in the range of HMOs close to human milk in quantity (8g/L) and 
diversity (more than 100 different structures of short- and long-chain types in a ratio of 9:1).Although 
this prebiotic mixture approaches the molecule size distribution of short- and long-chain 
oligosaccharides in human milk, it is not structurally similar to HMOs [77]. Clinical research on 
scGOS/lcFOS (9:1) showed benefits linked to modulation of the gut microbiota and the immune 
system, reduced incidence of infections, and stool softening [76,78,79]. This prebiotic mixture has 
been recognised as a prebiotic by ISAPP [70], and it may be added to infant formula and follow-on 
formula according to the Commission Delegated Regulation (EU) 2016/127 [80]. However, to date, 
there are no health claims granted by the European Food Safety Authority (EFSA) for the application 
of any oligosaccharides in infant formula. 
In addition to prebiotics based on GOS and/or FOS, infant formulas have recently been 
supplemented with specific technically derived HMOs (e.g., 2’-FL and LNnT), which have been 
anticipated as candidate prebiotics [70] (see Section 3.3). 
3.3. Specific HMOs Added to and/or Present in Infant Formula 
Recent research highlights the variety of HMOs in human milk, underlining the importance of 
scientific assessment of the role of both minor and major oligosaccharides in promoting infant health 
before adding it to infant formula.  
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Technically, only 2’-FL and LNnT are currently commercially available for addition to infant 
formula as purified ingredients [81]. The technology used for obtaining these is the coupling of 
bacterial homogenates or the utilisation of E. coli as a microbial cell factory (see Table 1). Other 
technologies are available but, currently, only used for analytical and research purposes. While 2′-FL 
and LNnT are obtained by chemical synthesis, 3’-GL occurs as a bacterial by-product during milk 
fermentation [12,13]. Besides these three examples, further HMOs are in the pipeline for application 
in infant formula [81]. 
Table 1. Current technologies for obtaining commercially available HMOs for application in infant 
formula (data on 2’FL and LNnT are adapted from Bych et al. [81], data on 3’-GL from Rodriguez-
Herrera et al. [12]). 




Isolation from human milk 
For structural identification and fundamental 
research applications only 
[40,82–
84] 
Chemo-enzymatic synthesis using 
recombinantly expressed glycosyltransferases 
matched with nucleotide-activated donor 
substrates and acceptors 
For generating libraries of asymmetrical multi-
antennary HMOs for research purposes only 
[85] 
Chemical synthesis from L-fucose, D-
galactose, N-acetyl-D-glucosamine, and D-
lactose, respectively 
Prohibitively expensive for large-scale nutrition 
applications due to complexity, number of 
reaction steps, limited availability, and high cost 
of raw materials 
[86–89] 
Coupling of the bacterial homogenates of two 
or more recombinant microbial cells 
overexpressing genes for HMO synthesis 
For the industrial manufacturing of LNnT and 
fucosylated oligosaccharides 
[90,91] 
Microbial fermentation of engineered E. coli 
strains for fucosylation reaction (complete 
removal of the strain and all other non-
desired biomolecules after fermentation) 
Used for both research and viable commercial 
production with high titers of 2’-FL and LNnT 
[92] 
3’-GL 
Milk fermentation process using 
Bifidobacterium breve C50 and Streptococcus 
thermophilus 065 and providing 3’-GL as a 
metabolic by-product at levels of ~250 µg/mL 
Proprietary fermentation process (LactofidusTM) 
for large-scale production of fermented infant 
formula 
[12] 
3.3.1. HMOs 2′-FL and LNnT 
2’-FL and LNnT have been anticipated as candidate prebiotics [70]. Although manufactured 
HMOs are structurally identical to their counterparts in human milk, regulatory approval is required 
for novel foods by the European Union (Commission Implemented Regulation (EU) 2017/2470) [93]. 
The EFSA Scientific Panel on Nutrition recently assessed 2’-FL, difucosyllactose (DFL), LNnT, and 
LNT as safe for use in infant formula [94–96]. Furthermore, 2’-FL, DFL, LNnT, and LNT have been 
added to the GRAS-list derived from the FDA [97].  
Preclinical research has shown that synthetic 2’-FL (with an identical structure as the 2’-FL found 
in human milk and often prepared from lactose) has prebiotic effects and may deliver functional 
benefits in infants. In preclinical trials, 2’-FL promoted the growth of specific bifidobacteria [98,99], 
blocked the growth of pathogens [100–102], and supported gut maturation and the stimulation of the 
gut intestinal barrier [103]. Furthermore, 2’-FL impacted neuronal dependent gut migrating motor 
complexes, suggesting beneficial effects on the central nervous system [104]. 
Infant formulas containing 2.4 g total oligosaccharides/L (control: scGOS only; experimental 
formulas: scGOS + 0.2 or 1.0 g 2’-FL/L) have been demonstrated to be safe in terms of normal growth 
and were well-tolerated in a prospective, randomised, an controlled growth and tolerance study with 
189 healthy, singleton infants [9]. A post-hoc analysis of this study revealed that infants receiving 0.2 
g/L 2’-FL had a significantly reduced incidence of respiratory infections as compared to the control 
group receiving scGOS alone. This effect was not seen in the group receiving 1.0 g/L 2’-FL [10]. A 
further analysis of the same study showed that infants who received the 2’-FL-containing formulas 
had significantly lower plasma inflammatory cytokines compared to infants who received the control 
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formula, closely resembling the levels found in the breastfed reference group, potentially indicative 
of an anti-inflammatory effect [8]. 
A recently developed infant formula concept combines a prebiotic mixture of scGOS/lcFOS (9:1) 
and 2’-FL to further mimic the complex composition of HMO structures and their functional benefits. 
Data from the first in vivo pre-clinical investigations showed positive effects of this combination in a 
rotavirus model [105] and in a vaccination model [32,106]. 
LNnT has been assessed in vitro for function as a prebiotic inducing growth and metabolic 
activity in Bifidobacterium infantis [107]. As an ingredient, LNnT proved to be a stable and safe 
component of infant formula that was evaluated for its ability to reduce oropharyngeal colonisation 
with Streptococcus pneumoniae in children (6 months or older). Although colonisation was not reduced, 
LNnT proved to be well-tolerated at the tested concentration of 200 mg/L [107].  
Infant formula supplemented with a combination of 2’-FL (1.0 g/L) and LNnT (0.5 g/L) was 
demonstrated to be safe and well-tolerated and to support age-appropriate growth in a multicentre, 
randomised, double-blind trial with 175 healthy infants, with weight gain as a primary study 
outcome. Secondary outcomes were also found including associations of lower parent-reported 
morbidity  (particularly bronchitis) and medication use (antipyretics and antibiotics) in infants fed 
the supplemented formula compared to the control [11]. 
3.3.2. HMO 3’-GL 
HMO 3’-GL is naturally present in human milk and was already isolated from human milk in 
1988 [40]. Recently, a single chromatography run using an improved sample pre-treatment method 
and ultrahigh pressure liquid chromatography with fluorescence detection quantified 15 sialylated 
and neutral HMOs with high sensitivity, identifying 3'-GL and 6'-GL in colostrum, transitional, and 
mature human milk [108]. Human milk from mothers with preterm delivery revealed 3’-GL 
concentrations of 4–28.82 µg/mL (median 10.44) at 1 w postpartum, whereas concentrations ranged 
from 4–32.97 µg/mL (median 12.34) in colostrum and 4–20.73 µg/mL (median 4) at 8 w postpartum 
from mothers with term delivery [46]. Further human milk analyses of mothers with term delivery 
revealed 47–79 µg/mL of 3’-GL in colostrum [109], 5.080.45 µg/mL (mean  SD) in colostrum, and 
4.840.48 µg/mL (mean  SD) at 100 d of lactation [39], and 0.5–39 µg/mL (median 4.6) in milk pooled 
until 21 d of lactation [38]. 
In pre-clinical studies, 3’-GL, 4’-GL, and 6’-GL prepared from colostrum individually accounted 
for specific immunomodulation of polyinosinic:polycytodylic acid-induced interleucin-8 levels in an 
immature human intestine tested at a concentration of 200 µg/mL each [110]. Another study reported 
that a solution of 5 mg galactosyloligosaccharides/mL, which was synthesized from lactose and 
comprised of 14 % 3’-GL, 8 % 4’-GL, and 12 % 6’-GL, demonstrated ex vivo anti-inflammatory effects 
by attenuating the nuclear transcription factor κB inflammatory signalling in human intestinal 
epithelial cells [38]. In a model for intestinal barrier function using human intestinal epithelial Caco-
2 cell monolayers grown in a transwell system, 3’-GL chemically synthesised from lactose was able 
to protect the intestinal barrier against breakdown of intestinal integrity, whereas alpha-3’-GL (with 
an α1-3 glycosidic linkage), 4’-GL, and 6’-GL (all chemically synthesized from lactose) demonstrated 
no significant results [109]. Previously, a commercial mixture of galacto-oligosaccharides also 
demonstrated a barrier-stabilising effect and resulted in improved integrity of the intestinal barrier 
function and reduced inflammatory response by using the same in vitro method [111]. 
Although these first pre-clinical data may indicate that certain galactosyllactoses, such as 3’-GL, 
have protective and immunomodulatory effects in the gut, more research is needed to further explore 
their role as HMOs. 
Since 3’-GL in infant formula is a fermentation by-product, the safety of 3’-GL can be considered 
assured by the long history of safe use of the fermented formula in France [112]. The clinical evidence 
available on fermented infant formula is summarized in Section 3.5.3.  
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3.4. Synbiotics 
Beneficial synergistic effects may be expected from a combination of probiotics and prebiotics, 
which are called synbiotics, using prebiotics to selectively increase abundance of both endogenous 
beneficial bacteria and beneficial microbes in the infant gut [113]. 
Given the evidence for an aberrant gut microbiota in infants with allergy [114,115] and the key 
role of the gut microbiota on immune system maturation [116], there is a strong rationale for 
developing a suitable pre- and probiotic (synbiotic) blend for use in infant formula for infants at high 
risk of allergy and infants with already developed allergy. A synbiotic mixture of prebiotics 
(scGOS/lcFOS or scFOS/lcFOS in a ratio of 9:1) and the probiotic strain Bifidobacterium breve M-16V 
already demonstrated promising results. This synbiotic combination compensated for delayed 
bifidobacteria colonisation in infants delivered by caesarean section (compared to vaginally delivered 
infants) in an exploratory, randomised, double-blind, controlled study with 153 infants with 
detection of total faecal bifidobacteria as primary study outcome [117]. Secondary outcomes 
demonstrated a lower proportion of potential pathogens (e.g., clostridia-related species) [118], lower 
faecal pH, and significant changes in SCFA pattern (e.g., higher acetate and lower butyric, isobutyric, 
and isovaleric acids) [119]. Furthermore, this synbiotic blend led to a significant decrease of SCORAD 
(Scoring Atopic Dermatitis) score in infants with atopic dermatitis (AD) and greater improvement of 
SCORAD score in infants with IgE (immunoglobulin E)-associated AD [119]. At the 1-year follow-up 
of this study, children with AD in the synbiotics group showed less asthma-like symptoms (frequent 
wheezing and wheezing and/or noisy breathing apart from colds) and asthma medication use [120].  
However, even if some synbiotic combinations already display promising clinical results in 
infants, more randomised trials with longer follow-up are needed for the determination of their 
physiological and metabolic impact on the host [113]. 
3.5. Postbiotics 
In contrast to probiotics, bacterial viability in postbiotics is not seen as an essential requirement 
for health benefits, providing a potential opportunity to foods that are not convenient for carrying 
viable bacteria [121], e.g., liquid infant formula. 
In infant formulas, the concept of postbiotics is yet to be defined, although specific fermented 
infant formulas with postbiotics have been commercially available in Europe for decades. So far, most 
known postbiotics are derived from Lactobacillus and Bifidobacterium strains, which are also generally 
the most used probiotics [65]. 
3.5.1. Definition of postbiotics 
Recently, a provisional definition has been formulated that stipulates that postbiotics are 
compounds produced by microorganisms and released from food components or microbial 
constituents, including non-viable cells that, when administered in adequate amounts, promote 
health and well-being [65].  
Examples of postbiotics have been summarised as follows [65]:  
 Compounds deriving from bacterial metabolism, such as exopolysaccharides, vitamins, lactic 
acid, bacteriocins, enzymes, surfactants, antioxidants, and SCFAs.  
 Complex molecules released from food compounds (enzymatically produced during food 
fermentation), such as peptides and galacto-oligosaccharides, e.g., 3’-GL and 6‘-GL.  
 Components released from lysed cells including DNA, RNA, cell walls and, perhaps, other 
cytoplasmic components, and surface layer proteins. 
A consensus definition on postbiotics is currently being formulated by ISAPP [122]. 
3.5.2. Postbiotics through fermentation 
For many thousands of years, fermentation of food has been applied as a natural process to 
generate foods with particular properties, palatability, taste, and health benefits [113]. Most health 
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benefits of fermented functional foods are accomplished by either the live microorganisms ingested 
or by postbiotics deriving from these microorganisms [65].  
For cow’s milk-based infant formulas, fermentation processes typically use lactic acid-producing 
bacteria as a starter culture [65]. In addition to lactose consumption during fermentation, microbial 
enzymatic transgalactosylation can transform lactose into other lactose-based biomolecules, with 3’-
GL as the major trisaccharide produced by Streptococcus thermophilus (e.g., Streptococcus thermophilus 
065) from lactose fermentation [13]. The fermentation process is usually followed by physical 
treatment, which may include homogenisation, pasteurisation, sterilisation, and/or spray-drying 
[123].  
Recently, a specific fermentation process has been developed for infant nutrition, using two 
specific types of food-grade lactic acid producing microorganisms (Bifidobacterium breve C50 and 
Streptococcus thermophilus 065) and naturally delivering postbiotics [12,124,125]. 
3.5.3. Benefits of postbiotics in infant formula 
In a mouse model, infant formula containing postbiotics deriving from a specific fermentation 
process combined with prebiotic scGOS/lcFOS (9:1) stimulated morphological (i.e., crypt villus length 
in ileum) and functional (i.e., ileal sucrase activity, gut permeability) gut maturation more similar to 
the mother-fed situation than infant formula without pre- or postbiotics [126]. Gut permeability 
measured by fluorescein isothiocyanate-dextran was similar in mice receiving post- and prebiotics 
and mother-fed mice, while it was significantly lower in mice receiving the control infant formula 
without post- or prebiotics (Figure 4). An early decrease in permeability, as observed in the control 
group, could have a lasting detrimental effect on health by changing immune maturation [127]. 
 
Figure 4. Gut permeability measured by fluorescein isothiocyanate (FITC)-dextran in mice fed infant 
formula (IF) containing postbiotics deriving from a specific fermentation process (LactofidusTM) and 
prebiotic scGOS/lcFOS (9:1) (PRE+POST) compared to IF with prebiotics only (PRE), control IF 
without post- and prebiotics (CTRL), and mother-fed mice (MF); data represent mean + standard error 
of the mean (SEM); one-way ANOVA + post-test; *p ≤ 0.05 [126]. Results derive from a congress 
abstract and are currently in preparation for full publication. Courtesy of Dr A. Vincent, Dr I. Renes 
and Dr I. Van Seuningen. 
The first clinical study with a fermented infant formula was already published in 1989, reporting 
positive effects on gut function [128]. More recently, specific postbiotics deriving from fermentation 
have been reported to positively affect the gut microbiota, metabolic pathways, and immune 
responses [4,129,130].  
Specifically, an infant formula fermented by Bifidobacterium breve C50 and Streptococcus 
thermophilus 065—with and without prebiotic scGOS/lcFOS (9:1)—demonstrated its capacity to 
impact immune and gut health benefits in otherwise healthy infants (Table 2). Since fermented 
formulas may consist of a variety of bacterial metabolites, their benefits cannot be attributed to any 
single metabolite alone. 
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In a recent systematic review, limited evidence was demonstrated for specific postbiotics being 
recommended for treating paediatric diarrhoea and preventing common infectious diseases among 
children. For therapeutic trials, supplementation with heat-inactivated Lactobacillus acidophilus LB 
reduced the duration of diarrhoea, and for preventive trials, heat-inactivated Lactobacillus paracasei 
CBA L74 reduced the risk of diarrhoea, pharyngitis, and laryngitis [131]. 
Table 2. Impact of infant formula fermented with Bifidobacterium breve C50 and Streptococcus 





Diet (no. of 
Infants) 
Impact (fermented vs. Standard 
Formula Group) 
Ref 
Impact on immune parameters 
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infants 
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Reduced severity of 
acute diarrhoea (no effect on 
incidence and duration of 
diarrhoea episodes and number 








formula (30); HM 
(30) 
Enhanced thymus size (fermented 












Lower faecal calprotectin and 












Less positive SPT to cow’s milk 
(no effect on CMA incidence) and 
lower incidence of digestive and 
respiratory potentially allergic 
AEs 
[136] 
Impact on gut parameters  




28 d until 




formula (86); HM 
(90) 
Softer stool consistency 
(fermented formula group closer 
to HM) 
No differences regarding parent-
reported GI (and related) 
symptoms and investigator- 
reported AEs (except lower 
incidence of infantile colic) 
[12] 
Subset of 30 
infants per study 
arm 
Stools: lower pH, higher levels of 
acetic acid and sIgA, increased 
Bifidobacterium sp, and decreased 
Clostridium difficile occurrence 
(gut microbiota composition of 
fermented formula group closer 
to HM) 
[137] 
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1 Based on a recently developed fermentation process (LactofidusTM) generating bioactive compounds; 
one of these was 3’-GL at a level of ~250 µg/mL. Abbreviations: AE (adverse event), CMA (cow’s milk 
allergy), GA (gestational age), GI (gastrointestinal), HM (human milk), IgA (immunoglobulin A), SPT 
(skin prick test). Reference [137] is a congress abstract and is currently in preparation for full 
publication. 
In view of the suggested preclinical and clinical results, postbiotics should be considered as 
strain-specific as probiotics: each bacterial strain and each fermentation process generate unique cells, 
cell structures, and metabolites with varying functionalities, and the benefits need to be established 
according to the defined combination of the compounds. 
4. Conclusions 
Breastfeeding is the natural and optimal way of feeding an infant. Current research still focuses 
on infant formula aiming to more closely resemble the composition and functionality of human milk, 
with some already comprising probiotics, prebiotics, synbiotics, and postbiotics. Human milk 
naturally provides these components by delivering HMOs (‘natural prebiotics’) and beneficial 
bacteria (‘natural probiotics’) and their metabolites (‘natural postbiotics’). In infant formula, these 
nutritional concepts are provided by different pre- and probiotic mixtures and a mixture of both 
(synbiotics) and, additionally, by using partly fermented infant formula with beneficial compounds 
produced by microorganisms that are released from food components or microbial constituents, 
including non-viable cells (postbiotics). One of the most current examples of such compounds is 3'-
galactosyllactose (3'-GL), which is present in human milk and is a natural derivative of milk 
fermentation. Although such developments may pave the way for future infant formula alternatives 
for those infants who are not able to be (fully) breastfed, human milk feeding will always remain the 
unmatched goal for infant nutrition and development as well as provide many benefits for maternal 
health. 
Author Contributions: S.S. and H.S. wrote, reviewed, and edited the manuscript. B.S. reviewed and edited the 
manuscript (in particular the biological aspects and health benefits of HMOs). G.V. reviewed and edited the 
manuscript (in particular the technological aspects of HMO production). All authors have read and agreed to 
the published version of the manuscript. 
Funding: This research received no external funding. 
Acknowledgments: The authors are grateful to Jan Knol (Laboratory of Microbiology, Wageningen University, 
6708 WE Wageningen, The Netherlands), Johan Garssen (Division of Pharmacology, Utrecht Institute for 
Pharmaceutical Sciences, Faculty of Science, Utrecht University, 3584 CA Utrecht, The Netherlands), and Marko 
Mank for their support and scientific expertise. All three are employees of Danone Nutricia Research, 3584 CT 
Utrecht, The Netherlands. 
Conflicts of Interest: B.S. is employee of Danone Nutricia Research, which has proprietary rights to the prebiotic 
mixture of scGOS/lcFOS (9:1), mentioned in Section 3.2, and to the fermentation process LactofidusTM, mentioned 
in Section 3.5.2 and in Tables 1 and 2. All other authors declare no conflict of interest. 
Abbreviations 
2′-FL 2′-fucosyllactose  
3‘-GL 3'-galactosyllactose 
4’-GL 4’-galactosyllactose 
AD atopic dermatitis 
AE adverse event 
ATCC American Type Culture Collection 
DFL difucosyllactose 
DP degree of polymerisation  
Caco adenocarcinoma of the colon 
CBA chocolate blood agar 
CFU colony forming units 
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CMA cow’s milk allergy 
DNA deoxyribonucleic acid 
DSM  Dutch State Mines 
EFSA European Food Safety Authority 
ESPGHAN European Society for Paediatric Gastroenterology, Hepatology and Nutrition 
FDA U.S. Food & Drug Administration 
FL fucosyllactoses 
FOS fructo-oligosaccharides 
FUT2 fucosyltransferase 2 
GOS galacto-oligosaccharides 
GL galactosyllactose 
GRAS generally recognized as safe 
HM human milk 
HMO human milk oligosaccharide 
IF infant formula 
IgE immunoglobulin E 
ISAPP International Scientific Association for Probiotics and Prebiotics 
kDa kilodalton 
LA Lactobacillus acidophilus 
LB lysogeny broth 
LNnT lacto-N-neotetraose 
LNT lacto-N-tetraose 
NCDO National Collection of Dairy Organism  
NCIMB National Collection of Industrial, Food and Marine Bacteria 
NEC necrotizing enterocolitis 
QPS qualitative presumption of safety 
RNA ribonucleic acid 
SCORAD scoring atopic dermatitis 
scGOS/lcFOS (9:1) short-chain GOS/long-chain FOS (in a ratio of 9:1)  
SCFA short-chain fatty acid 
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